Symphogen A/S Raises $186 Million to Advance Cancer-Drug Pipeline
5/2/2013 7:42:42 AM
More...
|
Symphogen A/S Presents New pan-HER data at Annual American Association for Cancer Research Meeting
4/10/2013 6:31:43 AM
More...
|
Symphogen A/S to Present at Annual J.P. Morgan Healthcare Conference
1/3/2013 9:59:21 AM
More...
|
Merck KGaA (MKGAF.PK) Inks $625 Million License Agreement With Symphogen A/S
9/6/2012 7:17:45 AM
More...
|
Symphogen A/S Publishes Final Rozrolimupab (SYM001) Phase 2 Trial Results in ITP in BLOOD Journal
8/22/2012 10:41:51 AM
More...
|
Symphogen A/S Names Martin Olin Chief Financial Officer and Receives 2nd Tranche From €100 Million 2011 Financing
4/2/2012 6:57:28 AM
More...
|
Symphogen A/S Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at American Society of Hematology
12/13/2011 6:46:13 AM
More...
|
Symphogen A/S to Present Rozrolimupab (SYM001) Final Data at 2011 American Society of Hematology Meeting
12/6/2011 6:31:19 AM
More...
|
Symphogen A/S Announces Initiation of Phase 2 Trial of Sym004 EGFR Antibody Mixture in Patients with Squamous Cell Carcinoma of Head and Neck Cancer
8/23/2011 8:49:26 AM
More...
|
Symphogen A/S Presents Preliminary Results from Phase 2 Clinical Trial with Rozrolimupab at the Annual European Hematology Association
6/10/2011 10:57:56 AM
More...
|
|